Ligand Pharmaceuticals (LGND) Scheduled to Report Q3 2026 Earnings
Ligand Pharmaceuticals (LGND) is set to release its third-quarter 2026 financial results on Thursday, October 29th, prior to the market opening. Investors are closely watching for performance metrics against consensus estimates. The market anticipates an earnings per share (EPS) of $2.33 and revenue of approximately $77.23 million. Notably, the projected revenue represents a significant year-over-year decline of 33.1%, which may serve as a focal point for investor sentiment during the call.
Tickers: $LGND